Rna-coded antibody

Patent metadata

Field	Value
Publication number	US-2016145346-A1
Application number	US-201615007072-A
Country	US
Kind code	A1
Filing date	Jan 26, 2016
Priority date	Jan 9, 2007
Publication date	May 26, 2016
Grant date	—

Abstract

The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method.

First claim

What is claimed is:

1 . A method of treating a subject comprising administering an effective amount of a pharmaceutical composition comprising mRNA encoding an epidermal growth factor receptor (EGFR)-binding antibody.

2 . The method of claim 1 , wherein the subject has a cancer.

3 . The method of claim 2 , wherein the subject has a colorectal cancer.

4 . The method of claim 1 , wherein the pharmaceutical composition is administered by injection.

5 . The method of claim 1 , wherein the antibody comprises a Fab, Fab′, F(ab′)2, Fc, pFc′, Fd, FIT and scFv fragment of an antibody.

6 . The method of claim 1 , wherein the mRNA comprises a sequence encoding an antibody operably linked to a heterologous secretory signal sequence.

7 . The method of claim 1 , wherein the composition comprises a mRNA that encodes an antibody light chain and a mRNA that encodes an antibody heavy chain.

8 . The method of claim 1 , wherein the composition comprises a mRNA that encodes an antibody light chain and an antibody heavy chain, wherein the antibody light chain and an antibody heavy chain coding sequences are linked by an internal ribosomal entry site (IRES).

9 . The method of claim 1 , wherein the mRNA comprises a 5′ cap structure.

10 . The method of claim 1 , wherein the mRNA additionally comprises a poly-A tail of 10 to 200 adenosine nucleotides and/or a poly-C tail of 10 to 200 cytosine nucleotides.

11 . The method of claim 1 , wherein the EGFR-binding antibody comprises cetuximab, panitumumab, nimotuzumab or pertuzumab.

12 . The method of claim 11 , wherein the antibody comprises cetuximab.

13 . The method of claim 12 , wherein the mRNA encodes: a sequence at least 80% identical to SEQ ID NOs: 6 or 7; and/or a sequence at least 80% identical to SEQ ID NOs: 8 or 9.

14 . The method of claim 1 , wherein the mRNA is modified by introduction of a nonnative nucleotide compared with a native mRNA sequence and/or by covalent coupling of the mRNA with a further chemical moiety.

15 . The method of claim 14 , wherein the mRNA comprises:
(i) a G/C content in the antibody coding region which is greater than the G/C content of the coding region of the native mRNA sequence encoding the antibody; or (ii) an antibody coding sequence that is modified, compared with the native mRNA encoding the antibody, such that at least one codon of the native mRNA which codes for a tRNA which is relatively rare in the cell is exchanged for a codon which codes for a tRNA which is relatively frequent in the cell.

16 . The method of claim 14 , wherein the mRNA comprises a chemical modification relative to a naturally occurring mRNA.

17 . The method of claim 14 , wherein the mRNA comprises at least a nucleotide that is substituted with a nucleotide analog selected from the group consisting of: 1-methyl-adenine, 2-methyl-adenine, 2-methylthio-N-6-isopentenyl-adenine, N6-methyl-adenine, N6-isopentenyl-adenine, 2-thio-cytosine, 3-methylcytosine, 4-acetyl-cytosine, 5-methyl-cytosine, 2,6-diaminopurine, 1-methyl-guanine, 2-methyl-guanine, 2,2-dimethyl-guanine, 7-methyl-guanine, inosine, 1-methyl-inosine, dihydro-uracil, 2-thio-uracil, 4-thio-uracil, 5-carboxymethylaminomethyl-2-thio-uracil, 5-(carboxyhydroxymethyl)-uracil, 5-fluoro-uracil, 5-bromo-uracil, 5-carboxymethylaminomethyl-uracil, 5-methyl-2-thio-uracil, 5-methyl-uracil, N-uracil-5-oxyacetic acid methyl ester, 5-methylaminomethyl-uracil, 5-methoxyaminomethyl-2-thio-uracil, 5-methoxycarbonylmethyl-uracil, 5-methoxy-uracil, uracil-5-oxyacetic acid methyl ester, uracil-5-oxyacetic acid (v), pseudouracil, 1-methyl-pseudouracil, queosine, β-D-mannosyl-queosine, wybutoxosine, phosphoramidates, phosphorothioates, peptide nucleotides, methylphosphonates, 7-deazaguanosine, 5-methylcytosine and inosine.

18 . The method of claim 14 , wherein the mRNA modification comprises at least one base-modified nucleotide chosen from the group consisting of 2-amino-6-chloropurine riboside 5′-triphosphate, 2-aminoadenosine 5′-triphosphate, 2-thiocytidine 5′-triphosphate, 2-thiouridine 5′-triphosphate, 4-thiouridine 5′-triphosphate, 5-aminoallylcytidine 5′-triphosphate, 5-aminoallyluridine 5′-triphosphate, 5-bromocytidine 5′-triphosphate, 5-bromouridine 5′-triphosphate, 5-iodocytidine 5′-triphosphate, 5-iodouridine 5′-triphosphate, 5-methylcytidine 5′-triphosphate, 5-methyluridine 5′triphosphate, 6-azacytidine 5′-triphosphate, 6-azauridine 5′-triphosphate, 6-chloropurine riboside 5′-triphosphate, 7-deazaadenosine 5′-triphosphate, 7-deazaguanosine 5′-triphosphate, 8-azaadenosine 5′-triphosphate, 8-azidoadenosine 5′-triphosphate, benzimidazole riboside 5′-triphosphate, N1-methyladenosine 5′-triphosphate, N1-methylguanosine 5′-triphosphate, N6-methyladenosine 5′-triphosphate, O6-methylguanosine 5′-triphosphate, pseudouridine 5′-triphosphate, puromycin 5′-triphosphate and xanthosine 5′-triphosphate.

19 . The method of claim 18 , wherein the base-modified nucleotide is chosen from the group consisting of: 5-methylcytidine 5′-triphosphate, 1-methyl-pseudouracil and pseudouridine 5′-triphoshate.

20 . A pharmaceutical composition comprising an isolated mRNA comprising a coding region encoding at least one antibody variable domain of an EGFR-binding antibody, wherein said coding region linked to a heterologous secretory signal sequence.

Assignees

• Curevac Ag

Inventors

• Hoerr Ingmar
• Probst Jochen
• Pascolo Steve

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P33/00

  Antiparasitic agents · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title